![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SRSF2 |
Gene summary for SRSF2 |
![]() |
Gene information | Species | Human | Gene symbol | SRSF2 | Gene ID | 6427 |
Gene name | serine and arginine rich splicing factor 2 | |
Gene Alias | PR264 | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | A0A024R8U5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6427 | SRSF2 | GSM4909277 | Human | Breast | Precancer | 4.52e-02 | 4.88e-01 | 0.0177 |
6427 | SRSF2 | GSM4909280 | Human | Breast | Precancer | 8.73e-04 | 3.68e-01 | 0.0305 |
6427 | SRSF2 | GSM4909281 | Human | Breast | IDC | 7.75e-03 | 1.95e-01 | 0.21 |
6427 | SRSF2 | GSM4909282 | Human | Breast | IDC | 2.78e-12 | 3.65e-01 | -0.0288 |
6427 | SRSF2 | GSM4909286 | Human | Breast | IDC | 7.70e-07 | 1.34e-01 | 0.1081 |
6427 | SRSF2 | GSM4909293 | Human | Breast | IDC | 1.46e-07 | 2.92e-01 | 0.1581 |
6427 | SRSF2 | GSM4909294 | Human | Breast | IDC | 8.58e-04 | -1.80e-01 | 0.2022 |
6427 | SRSF2 | GSM4909296 | Human | Breast | IDC | 1.56e-17 | -5.40e-01 | 0.1524 |
6427 | SRSF2 | GSM4909297 | Human | Breast | IDC | 9.18e-21 | 6.86e-02 | 0.1517 |
6427 | SRSF2 | GSM4909298 | Human | Breast | IDC | 1.68e-08 | 3.42e-01 | 0.1551 |
6427 | SRSF2 | GSM4909301 | Human | Breast | IDC | 4.57e-02 | -2.94e-01 | 0.1577 |
6427 | SRSF2 | GSM4909308 | Human | Breast | IDC | 5.86e-04 | 2.22e-01 | 0.158 |
6427 | SRSF2 | GSM4909311 | Human | Breast | IDC | 1.11e-38 | -5.28e-01 | 0.1534 |
6427 | SRSF2 | GSM4909312 | Human | Breast | IDC | 4.47e-11 | 5.64e-02 | 0.1552 |
6427 | SRSF2 | GSM4909319 | Human | Breast | IDC | 1.64e-51 | -4.47e-01 | 0.1563 |
6427 | SRSF2 | GSM4909320 | Human | Breast | IDC | 1.95e-05 | -3.04e-01 | 0.1575 |
6427 | SRSF2 | GSM4909321 | Human | Breast | IDC | 1.74e-20 | 6.06e-02 | 0.1559 |
6427 | SRSF2 | brca2 | Human | Breast | Precancer | 2.50e-05 | 6.35e-02 | -0.024 |
6427 | SRSF2 | brca10 | Human | Breast | Precancer | 5.14e-10 | -5.28e-01 | -0.0029 |
6427 | SRSF2 | NCCBC14 | Human | Breast | DCIS | 2.06e-09 | -3.38e-01 | 0.2021 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0043484110 | Oral cavity | LP | regulation of RNA splicing | 81/4623 | 148/18723 | 4.34e-15 | 5.79e-13 | 81 |
GO:005068418 | Oral cavity | LP | regulation of mRNA processing | 76/4623 | 137/18723 | 1.14e-14 | 1.35e-12 | 76 |
GO:190331119 | Oral cavity | LP | regulation of mRNA metabolic process | 129/4623 | 288/18723 | 5.70e-14 | 6.10e-12 | 129 |
GO:0048024110 | Oral cavity | LP | regulation of mRNA splicing, via spliceosome | 57/4623 | 101/18723 | 9.06e-12 | 6.84e-10 | 57 |
GO:0031667110 | Oral cavity | LP | response to nutrient levels | 165/4623 | 474/18723 | 3.87e-07 | 1.12e-05 | 165 |
GO:000038017 | Oral cavity | LP | alternative mRNA splicing, via spliceosome | 38/4623 | 77/18723 | 2.47e-06 | 5.43e-05 | 38 |
GO:000758414 | Oral cavity | LP | response to nutrient | 65/4623 | 174/18723 | 1.31e-04 | 1.52e-03 | 65 |
GO:000038117 | Oral cavity | LP | regulation of alternative mRNA splicing, via spliceosome | 27/4623 | 60/18723 | 4.71e-04 | 4.43e-03 | 27 |
GO:003327311 | Oral cavity | LP | response to vitamin | 37/4623 | 93/18723 | 9.14e-04 | 7.79e-03 | 37 |
GO:00331971 | Oral cavity | LP | response to vitamin E | 7/4623 | 11/18723 | 7.01e-03 | 3.96e-02 | 7 |
GO:190331124 | Oral cavity | EOLP | regulation of mRNA metabolic process | 102/2218 | 288/18723 | 8.13e-26 | 2.44e-22 | 102 |
GO:004348426 | Oral cavity | EOLP | regulation of RNA splicing | 59/2218 | 148/18723 | 2.64e-18 | 5.27e-15 | 59 |
GO:000838025 | Oral cavity | EOLP | RNA splicing | 115/2218 | 434/18723 | 2.24e-17 | 3.04e-14 | 115 |
GO:005068424 | Oral cavity | EOLP | regulation of mRNA processing | 55/2218 | 137/18723 | 2.54e-17 | 3.04e-14 | 55 |
GO:004802425 | Oral cavity | EOLP | regulation of mRNA splicing, via spliceosome | 42/2218 | 101/18723 | 3.41e-14 | 1.28e-11 | 42 |
GO:000037725 | Oral cavity | EOLP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 80/2218 | 320/18723 | 4.20e-11 | 5.60e-09 | 80 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
hsa030404 | Colorectum | MSI-H | Spliceosome | 37/797 | 217/8465 | 2.49e-04 | 3.23e-03 | 2.70e-03 | 37 |
hsa030405 | Colorectum | MSI-H | Spliceosome | 37/797 | 217/8465 | 2.49e-04 | 3.23e-03 | 2.70e-03 | 37 |
hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRSF2 | SNV | Missense_Mutation | novel | c.156N>C | p.Lys52Asn | p.K52N | Q01130 | protein_coding | tolerated(0.06) | benign(0.243) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
SRSF2 | SNV | Missense_Mutation | c.407C>G | p.Ser136Cys | p.S136C | Q01130 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
SRSF2 | SNV | Missense_Mutation | c.205N>A | p.Glu69Lys | p.E69K | Q01130 | protein_coding | deleterious(0.05) | possibly_damaging(0.64) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
SRSF2 | SNV | Missense_Mutation | c.205G>A | p.Glu69Lys | p.E69K | Q01130 | protein_coding | deleterious(0.05) | possibly_damaging(0.64) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SRSF2 | SNV | Missense_Mutation | c.311G>A | p.Gly104Glu | p.G104E | Q01130 | protein_coding | tolerated(0.5) | benign(0.346) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SRSF2 | SNV | Missense_Mutation | c.143N>G | p.Asp48Gly | p.D48G | Q01130 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SRSF2 | SNV | Missense_Mutation | novel | c.560N>A | p.Ser187Tyr | p.S187Y | Q01130 | protein_coding | deleterious(0.02) | benign(0.166) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SRSF2 | SNV | Missense_Mutation | rs755334722 | c.425N>T | p.Ser142Phe | p.S142F | Q01130 | protein_coding | deleterious(0.03) | possibly_damaging(0.601) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRSF2 | SNV | Missense_Mutation | novel | c.470N>A | p.Ser157Tyr | p.S157Y | Q01130 | protein_coding | deleterious(0) | benign(0.332) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRSF2 | SNV | Missense_Mutation | novel | c.631A>G | p.Lys211Glu | p.K211E | Q01130 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6427 | SRSF2 | CLINICALLY ACTIONABLE | H3B-8800 | |||
6427 | SRSF2 | CLINICALLY ACTIONABLE | N/A | 26508027,26769228 |
Page: 1 |